Eli Lilly and Company $LLY Stock Sold by Radnor Capital Management LLC

Radnor Capital Management LLC trimmed its holdings in Eli Lilly and Company (NYSE:LLY) by 12.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,267 shares of the company’s stock after selling 1,175 shares during the period. Eli Lilly and Company accounts for 1.3% of Radnor Capital Management LLC’s holdings, making the stock its 16th largest position. Radnor Capital Management LLC’s holdings in Eli Lilly and Company were worth $9,566,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in LLY. Integrity Financial Corp WA increased its stake in Eli Lilly and Company by 1.3% during the 2nd quarter. Integrity Financial Corp WA now owns 639 shares of the company’s stock worth $767,000 after acquiring an additional 8 shares during the period. LCM Capital Management Inc raised its holdings in Eli Lilly and Company by 3.3% in the 3rd quarter. LCM Capital Management Inc now owns 253 shares of the company’s stock valued at $293,000 after acquiring an additional 8 shares in the last quarter. Smith Shellnut Wilson LLC ADV lifted its position in shares of Eli Lilly and Company by 4.1% during the 3rd quarter. Smith Shellnut Wilson LLC ADV now owns 203 shares of the company’s stock valued at $235,000 after acquiring an additional 8 shares during the period. Willner & Heller LLC lifted its position in shares of Eli Lilly and Company by 1.0% during the 2nd quarter. Willner & Heller LLC now owns 917 shares of the company’s stock valued at $1,100,000 after acquiring an additional 9 shares during the period. Finally, Aspiring Ventures LLC grew its holdings in shares of Eli Lilly and Company by 3.7% during the 2nd quarter. Aspiring Ventures LLC now owns 255 shares of the company’s stock worth $306,000 after purchasing an additional 9 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CAO Donald Zakrowski sold 2,000 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares of the company’s stock, valued at $1,808,325.26. This represents a 56.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock worth $15,958,170 in the last three months. 0.14% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts recently commented on LLY shares. TD Cowen restated a “buy” rating and issued a $1,250.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, September 22nd. Guggenheim increased their price objective on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a research note on Friday, September 18th. Leerink Partners raised their target price on shares of Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the company an “outperform” rating in a report on Wednesday, October 21st. BMO Capital Markets reissued an “outperform” rating on shares of Eli Lilly and Company in a report on Thursday, October 1st. Finally, HSBC boosted their target price on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the company a “reduce” rating in a research report on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,320.25.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $1,283.52 on Wednesday. Eli Lilly and Company has a 12 month low of $809.63 and a 12 month high of $1,321.21. The stock has a 50-day moving average price of $1,191.27 and a two-hundred day moving average price of $1,088.34.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same period last year, the company posted $6.31 EPS. The firm’s revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities analysts forecast that Eli Lilly and Company will post 33.22 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Friday, November 13th.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: A federal judge rejected Novo Nordisk’s request to block Lilly’s advertisements for its obesity treatments, finding insufficient evidence that the campaign caused meaningful or lasting harm to Novo’s sales. The decision allows Lilly to continue promoting its weight-loss portfolio, including Zepbound. Reuters article
• Positive Sentiment: New early-stage oncology data added to Lilly’s pipeline narrative. Olomorasib reportedly produced a 62% response rate in lung-cancer data, while Phase 1 results for sofe-M plus bevacizumab showed encouraging response and disease-control rates in ovarian cancer without major new safety signals. These results remain preliminary but could support longer-term growth expectations. Lung cancer results
• Positive Sentiment: Bernstein raised its price target for LLY to $1,450 from $1,385, reflecting continued confidence in Mounjaro, Zepbound and Lilly’s broader growth prospects. Commentary also notes that Lilly has significantly outperformed broader equities over the past five years. Bernstein price-target update
• Positive Sentiment: LillyDirect is working with Counsel Health on an AI-enabled, physician-led weight-management program, potentially expanding access and patient engagement around Lilly’s GLP-1 medicines. Counsel Health partnership
• Neutral Sentiment: International business chief Patrik Jonsson will retire at year-end after 36 years, with Ilya Yuffa becoming president of Lilly Global Markets on January 1, 2027. The planned transition is intended to support global expansion, but it introduces a leadership change investors will monitor. Lilly leadership announcement
• Neutral Sentiment: Lilly declared a quarterly dividend of $1.73 per share, payable December 10 to shareholders of record November 13. The 0.5% yield is modest, making the announcement more of a continuity signal than a major valuation catalyst. Dividend announcement
• Negative Sentiment: Ahead of earnings, analysts continue to flag pricing pressure, rising costs and intense competition from Novo Nordisk. Investors will focus on Mounjaro and Zepbound demand, patient growth, revenue realization and updated guidance; strong expectations increase the risk of a muted reaction if results or outlook fall short. Q3 earnings preview

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.